A5078365633- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Cancer survivorship and care
- Intestinal and Peritoneal Adhesions
- Intraperitoneal and Appendiceal Malignancies
- Genetic factors in colorectal cancer
- Childhood Cancer Survivors' Quality of Life
- Cervical Cancer and HPV Research
- Colorectal Cancer Surgical Treatments
- Sarcoma Diagnosis and Treatment
- Palliative Care and End-of-Life Issues
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Endometriosis Research and Treatment
- Multiple and Secondary Primary Cancers
- DNA Repair Mechanisms
- Cardiac, Anesthesia and Surgical Outcomes
- Angiogenesis and VEGF in Cancer
- Radiomics and Machine Learning in Medical Imaging
- Reproductive Biology and Fertility
- Family Support in Illness
- Bacterial Infections and Vaccines
National Health and Medical Research Council
2019-2025
The University of Sydney
2019-2025
Royal Hospital for Women
2021-2025
UNSW Sydney
2021-2025
Prince of Wales Hospital
2019-2024
Chris O’Brien Lifehouse
2019-2023
Prince of Wales Hospital
2023
Cooperative Trials Group for Neuro-Oncology
2022
Australia New Zealand Gynaecological Oncology Group
2022
University of Toronto
2016-2020
In this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts women with advanced endometrial cancers (AEC)-mismatch repair proficient (pMMR) and mismatch deficient (dMMR).A multicenter phase study was performed AEC pMMR tumor progressing after one three lines chemotherapy dMMR zero chemotherapy. Mismatch status based on immunohistochemistry expression. All received durvalumab 1500 mg given every 4 weeks until progression or unacceptable...
Abstract Purpose: PARP inhibitors (PARPi) are standard-of-care therapy for high-grade serous ovarian cancer (HGSOC). We investigated combining cediranib (antiangiogenic) with olaparib at emergence of PARPi resistance. Patients and Methods: The proof-of-concept EVOLVE study (NCT02681237) assessed cediranib–olaparib combination after progression on a PARPi. Women HGSOC radiographic evidence disease were enrolled into one three cohorts: platinum sensitive PARPi; resistant or standard...
LBA3 Background: Cervical cancer is a common cause of cancer-related death among women worldwide. Standard treatment for locally advanced disease chemoradiation. However, significant percentage still relapse and die from the development distant metastatic disease. OUTBACK was designed to determine effects giving adjuvant chemotherapy after chemoradiation on survival. Methods: an international randomized phase III trial Gynecologic Cancer InterGroup (GCIG). Participating groups (countries)...
This study investigated the clinico-pathologic correlation of tumor angiogenesis in non-small-cell lung cancers. Formalin-fixed, paraffin-embedded surgical specimens 55 consecutive patients with primary cancers were examined. Included 26 squamous cell carcinomas and 29 adenocarcinomas. Twenty-five had stage I disease, eight II 22 IIIA or IIIB disease. Among them, 28 nodal metastasis 27 did not. The microvessel was demonstrated by immunocytochemical staining for factor VIII platelet...
Background. Despite the excellent immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines, breakthrough cases Hib disease still affect a small proportion vaccinated children in United Kingdom. We performed retrospective study to compare avidity antibody directed against polysaccharide capsule (PRP) who experienced vaccine failure Kingdom among 3 historical cohorts and with age-matched healthy control subjects. Methods. Serum samples from invasive were collected beginning...
Objective The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality life (HRQL) in women having for platinum resistant/refractory recurrent ovarian cancer (PRR-ROC) potentially sensitive with ≥3 lines (PPS-ROC ≥3). Methods Participants completed Measure Ovarian Symptoms Treatment (MOST) European Organization Research (EORTC) Quality Life Questionnaire QLQ-C30 questionnaires at baseline every 3–4...
Abstract Gender-affirming hormone therapy (GAHT) is increasingly prescribed to transgender men and gender diverse individuals better align their affirmed identity somatic phenotype, aiming improve psychosocial well-being. However, the long-term outcomes of GAHT, especially risk hormone-related malignancy, remains unclear. We report a case man on GAHT with testosterone who developed recurrent hormone-sensitive endometrioid ovarian cancer. Treatment medroxyprogesterone acetate effectively...
The emergence of targeted therapies has transformed ovarian cancer treatment. However, biomarker profiling for precision medicine is limited by access to quality, tumour‐enriched tissue samples. use cell‐free DNA (cfDNA) in ascites presents a potential solution this challenge. In study, next‐generation sequencing was performed on ascites‐derived cfDNA samples (26 from 15 human participants with cancer), matched tumour cells ( n = 5) and archived formalin‐fixed paraffin‐embedded (FFPE) 5)....
Abstract An increase in Haemophilus influenzae type b (Hib) British children has been linked to the widespread use of a diphtheria/tetanus/acellular pertussis combination vaccine (DTaP-Hib). We measured anti-polyribosyl-ribitol phosphate antibody concentration and avidity before after Hib booster 176 2–4 years age who had received 3 doses DTP-Hib (either DT whole cell pertussis-Hib or DTaP-Hib) infancy. also pharyngeal carriage Hib. Antibody concentrations indices vaccination were low...
Malignant bowel obstruction (MBO) is a common and distressing complication in women with advanced gynecologic cancer. A pilot, interprofessional MBO program was launched 2016 at large Canadian tertiary cancer center to integrate these patients' complex care needs across multiple disciplines support MBO.Retrospective analysis evaluate the outcomes of who were admitted hospital because MBO, before (2014 2016: baseline group) after (2016 2018) implementation program.Of 169 evaluated, 106 63...
5515 Background: Cyclin E1 gene amplification and protein over-expression is a marker of platinum resistance in high grade serous ovarian, fallopian tube or primary peritoneal cancer (HGSC), may predict response to WEE1 inhibition. Adavosertib, inhibitor, has demonstrated activity unselected women with recurrent ovarian endometrial cancer. We aimed evaluate the efficacy adavosertib resistant HGSC cyclin over-expression, without amplification. Methods: IGNITE multicentre, phase 2 trial...
<h3>Introduction/Background</h3> The standard therapy for advanced/recurrent endometrial cancer includes carboplatin and paclitaxel (CP). Robust biological rationale suggested a synergy between immunotherapy chemotherapy in this setting. <h3>Methodology</h3> AtTEnd is an academic study advanced or recurrent carcinoma/carcinosarcoma patients with no prior systemic recurrence. Patients were randomized (2:1 ratio) to receive either CP atezolizumab placebo, followed by placebo until disease...
<h3>Introduction/Background</h3> AtTEnd is a phase III randomized international academic trial showing the efficacy of atezolizumab in addition to standard carboplatin and paclitaxel (CP) patients (pts) with advanced/recurrent endometrial cancer. The potential for differences based on ethnicity unknown. <h3>Methodology</h3> In this post hoc analysis, we analyzed combination CP as maintenance vs alone comparing Asian cohort (AC) non-Asian (nAC). <h3>Results</h3> From Oct 2018 Jan 2022, 549...
Abstract Purpose Markman’s desensitisation protocol allows successful retreatment of patients who have had significant paclitaxel hypersensitivity reactions. We aimed to reduce the risk and severity reactions by introducing this as primary prophylaxis. Methods evaluated all with a gynaecological malignancy receiving before (December 2018 September 2019) after (October 2019 July 2020) implementation modified protocol. The pre-implementation group received over gradually up-titrated rate from...
TPS5637 Background: The treatment of recurrent epithelial ovarian cancer remains a challenge, particularly for tumors with low to moderate expression levels FRα. Luveltamab tazevibulin (luvelta) is an anti–FRα-targeting antibody-drug conjugate stable cleavable linker and 3-aminophenyl hemiasterlin warhead (DAR=4), which induces cytotoxic immunologic cell death. Luvelta was designed treat multiple cancers broad range FRα expression. demonstrated preliminary antitumor activity in women cancer,...
Background There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options limited in efficacy and tolerability. The combination avutometinib with defactinib has demonstrated a consistent safety profile two clinical trials recurrent cancer, lower discontinuation rate due to adverse events compared historical rates care. Primary Objective To compare the progression free survival versus investigator’s choice patients cancer. Study...